Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02511106 · OUTCOME

Overall Survival Rate at 2, 3 and 5 Years

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. · Source last updated 2026-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.

What was measured

Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.

Analysis population: Full Analysis Set (FAS) stage IIA-IIIA patients

Groups in this outcome

AZD9291 80mg Tablet

Taken once daily

Placebo Tablet

Taken once daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD9291 80mg Tablet233
Placebo Tablet237

Reported measurements

OS rate at 2 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet99.5Not reported96.899.9Not reported
Placebo Tablet92.6Not reported88.395.3Not reported
OS rate at 3 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet94.1Not reported90.196.5Not reported
Placebo Tablet85.9Not reported80.689.8Not reported
OS rate at 5 years (%)
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg Tablet85.0Not reported79.389.2Not reported
Placebo Tablet72.6Not reported66.078.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        96.8
        upper Limit
        99.9
        value
        99.5
      2. group Id
        OG001
        lower Limit
        88.3
        upper Limit
        95.3
        value
        92.6
    title
    OS rate at 2 years (%)
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        90.1
        upper Limit
        96.5
        value
        94.1
      2. group Id
        OG001
        lower Limit
        80.6
        upper Limit
        89.8
        value
        85.9
    title
    OS rate at 3 years (%)
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        79.3
        upper Limit
        89.2
        value
        85.0
      2. group Id
        OG001
        lower Limit
        66.0
        upper Limit
        78.1
        value
        72.6
    title
    OS rate at 5 years (%)
denoms
  1. counts
    1. group Id
      OG000
      value
      233
    2. group Id
      OG001
      value
      237
    units
    Participants
description
Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.
dispersion Type
95% Confidence Interval
groups
  1. description
    Taken once daily
    id
    OG000
    title
    AZD9291 80mg Tablet
  2. description
    Taken once daily
    id
    OG001
    title
    Placebo Tablet
param Type
NUMBER
population Description
Full Analysis Set (FAS) stage IIA-IIIA patients
reporting Status
POSTED
time Frame
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
title
Overall Survival Rate at 2, 3 and 5 Years
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice